Safety and Efficacy of Subretinal AAV-CRISPR Cas9 Gene Editing for Rhodopsin-Mutant Retinitis Pigmentosa: A Phase I IIa Dose-Escalation Triall. sjo 2026, 8 (2), 478-485. https://doi.org/10.37275/sjo.v8i2.137.